Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review

Bone Marrow Transplantation volume 39, pages 729–735 (2007)Cite this article

Abstract

Recombinant activated factor VII (rFVIIa) is an hemostatic agent that was originally developed for the treatment of hemorrhage in patients with hemophilia and inhibitors. However, in the last few years rFVIIa has been employed with success in a broad spectrum of congenital and acquired bleeding conditions. In this systematic review we present the current knowledge on the use of this drug in patients suffering from hemato-oncological disorders, which are quite commonly complicated by severe hemorrhage. On the whole, data in the literature suggest a potential role for rFVIIa in the management of bleeding unresponsive to standard therapy in patients with hematological malignancies, including those undergoing bone marrow transplant. However, the vast majority of the currently available data are derived from uncontrolled studies including single cases or small series of patients. Thus, further trials with larger numbers of patients are needed to establish the most appropriate doses and timing of rFVIIa and to assess its efficacy and safety in this setting.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Nègrier C, Lienhart A . Overall experience with Novoseven®. Blood Coagul Fibrinolysis 2000; 11 (Suppl 1): 19–24.

    Article  Google Scholar 

  2. Kessler CM . New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate. Curr Opin Hematol 2000; 7: 408–413.

    Article  CAS  Google Scholar 

  3. Hedner U, Erhardtsen E . Potential role for rFVIIa in transfusion medicine. Transfusion 2002; 42: 114–124.

    Article  CAS  Google Scholar 

  4. Franchini M, Zaffanello M, Veneri D . Recombinant factor VIIa. An update on its clinical use. Thromb Haemost 2005; 93: 1027–1035.

    Article  CAS  Google Scholar 

  5. Uhlmann EJ, Eby CS . Recombinant activated factor VIII for non-hemophiliac bleeding patients. Curr Opin Hematol 2004; 11: 198–204.

    Article  CAS  Google Scholar 

  6. Ghorashian S, Hunt BJ . ‘Off-license’ use of recombinant activated factor VII. Blood Rev 2004; 18: 245–259.

    Article  Google Scholar 

  7. Roberts HR, Monroe DM, White GC . The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858–3864.

    Article  CAS  Google Scholar 

  8. Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 41: 431–439.

    Google Scholar 

  9. Franchini M, Lippi G, Franchi M . The use of recombinant activated FVII in obstetrical and gynaecological haemorrhage. Br J Obstet Gynaecol 2007; 114: 8–15.

    Article  CAS  Google Scholar 

  10. Olajide O, Henke D, Gabriel DA . Hemorrhagic complications in bone marrow transplant: possible roles of recombinant activated coagulation factor VII. TATM 2006; 8 (Suppl 1): 27–34.

    Google Scholar 

  11. Pihusch M . Bleeding complications after hemopoietic stem cell transplantation. Semin Hematol 2004; 41 (Suppl 1): 93–100.

    Article  Google Scholar 

  12. Bacigalupo A . Hemopoietic stem cell transplants: the impact of haemorrhagic complications. Blood Rev 2003; 17: S6–S10.

    Article  Google Scholar 

  13. White B, Martin M, Kelleher S, Browne P, McCann SR, Smith OP . Successful use of recombinant FVIIa (Novoseven) in the management of pulmonary haemorrhage secondary to Aspergillus infection in a patient with leukemia and acquired FVII deficiency. Br J Haematol 1999; 106: 204–205.

    Article  Google Scholar 

  14. Vidarsson B, Onundarson P . Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost 2000; 83: 634–635.

    Article  CAS  Google Scholar 

  15. Billon S, Le Niger C, Escoffre-Barbe M, Vicariot M, Abgrall JF . The use of recombinant factor VIIa (NovoSeven) in a patient with FXI deficiency and a circulating anticoagulant. Blood Coagul Fibrinolysis 2001; 12: 551–553.

    Article  CAS  Google Scholar 

  16. Geroftziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M et al. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. Am J Hematol 2002; 69: 219–222.

    Article  Google Scholar 

  17. Prasad M, Winter SS, Frost JD, Hanrahan J, Schwartz M, Jones JE . Novel applications of recombinant factor VIIa for the management of pediatric coagulopathic diseases. J Pediatr Hematol/Oncol 2003; 25: 499–502.

    Article  Google Scholar 

  18. Zulfikar B, Kayran SM . Successful treatment of massive gastrointestinal hemorrhage in acute biphenotypic leukemia with recombinant factor VIIa (NovoSeven). Blood Coagul Fibrinolysis 2004; 15: 261–263.

    Article  Google Scholar 

  19. Osborne W, Bhandari S, Tait RC, Franklin IM . Immediate haemostasis with recombinant factor VIIa for haemorrhage following Hickman line insertion in acute myeloid leukaemia. Clin Lab Haematol 2004; 26: 229–231.

    Article  CAS  Google Scholar 

  20. Udvardy M, Telek B, Mezey G, Batar P, Altorjay I . Successful control of massive coumarol-induced acute upper gastrointestinal bleeding and correction of prothrombin time by recombinant active factor VII (Eptacog-alpha, NovoSeven) in a patients with a prosthetic aortic valve and two malignancies (chronic lymphoid leukaemia and lung cancer). Blood Coagul Fibrinolysis 2004; 15: 265–267.

    Article  Google Scholar 

  21. Zver S, Andoljsek D, Cerneic P . Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patients with acute promyelocytic leukaemia. Eur J Haematol 2004; 72: 455–456.

    Article  Google Scholar 

  22. Sallah S, Husain A, Nguyen P . Recombinant activated factor VII in patients with cancer and disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2004; 15: 577–582.

    CAS  PubMed  Google Scholar 

  23. De Fabritiis P, Dentamaro T, Picardi A, Cudillo L, Masi M, Amadori S . Recombinant factor VIIa for the management of severe hemorrhages in patients with hematologic malignancies. Haematologica 2004; 89: 243–245.

    CAS  PubMed  Google Scholar 

  24. Cervera JS, Mena-Duran AV, Piqueras CS . The use of recombinant factor VIIa in a patient with essential thrombocythaemia with uncontrolled surgical bleeding. Thromb Haemost 2005; 93: 383–384.

    Article  CAS  Google Scholar 

  25. Kurekci AE, Atay AA, Okutan V, Yavuz ST, Ozcan O . Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia. Blood Coagul Fibrinolysis 2005; 16: 145–147.

    Article  Google Scholar 

  26. André JM, Galambrun C, Trzeciak MC, Dargaud Y, Kaplan-Gouet C, Jallu V et al. Acquired Glanzmann's thromboasthenia asociated with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2005; 27: 554–557.

    Article  Google Scholar 

  27. Brenner B, Hoffman R, Balashov D, Shutluko E, Culic S, Nizamoutdinova E . Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII. Clin Appl Thromb/Hemost 2005; 1: 401–410.

    Article  Google Scholar 

  28. Veneri D, Franchini M . Successful treatment of intestinal hemorrhage in an Jehovah's witness patient. Am J Hematol 2005; 79: 343–345.

    Article  Google Scholar 

  29. Millar CG, Stringer MD, Sugarman I, Richards M . The use of recombinant factor VIIa for bleeding in paediatric practice. Haemophilia 2005; 11: 171–174.

    Article  CAS  Google Scholar 

  30. Das P, Carcao M, Hitzler J . Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia. Pediatr Blood Cancer 2006; 47: 206–209.

    Article  Google Scholar 

  31. Erikci AA, Ozturk A, Sayan O . Recombinant activated factor VII for severe uterine bleeding after chemotherapy in a woman with acute myeloid leukemia. Blood Coagul Fibrinolysis 2006; 17: 323–324.

    Article  Google Scholar 

  32. Ucar C, Caliskan U . Successful treatment of acute lymphoblastic leukemia with L-asparaginase-induced intracranial hemorrhage to activated recombinant factor VIIa in a child. Pediatr Hematol Oncol 2006; 23: 339–345.

    Article  Google Scholar 

  33. Culic S, Kuljis D, Armanda V, Jankovic S . Successful management of bleeding with recombinant factor VIIa (NovoSeven) in a patient with Burkitt lymphoma and thrombosis of the left femoral and left common iliac veins. Pediatr Blood Cancer 2006 [E-pub ahead of print].

  34. Mantzios G, Tsirigotis P, Pappa V, Spirou K, Giannopoulou V, Kaitsa I et al. Massive pulmonary embolism after treatment with rFVIIa in a thrombocytopenic patient with acute myelogenous leukemia and intractable bleeding. Eur J Haematol 2007; 78: 173–174.

    Article  Google Scholar 

  35. Blatt J, Gold SH, Wiley JM, Monahan PE, Cooper HC, Harvey D . Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant 2001; 28: 405–407.

    Article  CAS  Google Scholar 

  36. Hicks K, Peng D, Gajewski JL . Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. Bone Marrow Transplant 2002; 30: 975–978.

    Article  CAS  Google Scholar 

  37. Hoffman R, Eliakim R, Zuckerman T, Rowe JM, Brenner B . Successful use of recombinant activated factor VII in controlling upper gastrointestinal bleeding in a patient with relapsed acute myeloid leukemia. J Thromb Haemost 2003; 1: 606–608.

    Article  CAS  Google Scholar 

  38. Culligan DJ, Salamat A, Tait J, Westland G, Watson HG . Use of recombinant factor VIIa in life-threatening bleeding following autologous peripheral blood stem cell transplantation complicated by platelet refractoriness. Bone Marrow Transplant 2003; 31: 1183–1184.

    Article  CAS  Google Scholar 

  39. Pastores SM, Papadopoulos E, Voigt L, Halpern NA . Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation. Chest 2003; 124: 2400–2403.

    Article  Google Scholar 

  40. Ippoliti C, Hey D, Donato ML . Use of activated recombinant factor VII for treatment of pulmonary hemorrhage in stem cell transplantation recipients. Proc Am Soc Clin Oncol 2003; 22: 841.

    Google Scholar 

  41. Karimi M, Zakerinia M, Khojasteh HN, Ramzi M, Ahmad E . Successful treatment of cyclophosphamide induced intractable hemorrhagic cystitis with recombinant FVIIa after allogeneic bone marrow transplantation. J Thromb Haemost 2004; 2: 1853–1855.

    Article  CAS  Google Scholar 

  42. Henke D, Falk RJ, Gabriel DA . Successful treatment of diffuse alveolar hemorrhage with activated factor VII. Ann Intern Med 2004; 140: 493–494.

    Article  Google Scholar 

  43. Aneel AA, Gabriel DA, James LG, Nigel SK . Pilot study to test the efficacy and safety of Recombinant Factor VIIa (rFVIIa, NovoSeven) in the treatment of refractory hemorrhagic cystitis following high dose chemotherapy (Abstract). Blood 2004; 104: 1136.

    Google Scholar 

  44. Pihusch M, Bacigalupo A, Szer J, von Depka Prondzinski M, Gaspar-Blaudschun B, Hyveled L et al. F7BMT-1360 Trial Investigators. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost 2005; 3: 1935–1944.

    Article  CAS  Google Scholar 

  45. Eller P, Pechlaner C, Wiedermann CJ . Ineffective off-label use of recombinant activated factor VII in a case of bone-marrow-transplantation-related-gastrointestinal bleeding. Thromb J 2006; 4: 1.

    Article  CAS  Google Scholar 

  46. Hoffman M, Monroe III DM . The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol 2001; 38: 6–9.

    Article  CAS  Google Scholar 

  47. Lisman T, De Groot PG . Mechanism of action of recombinant factor VIIa. J Thromb Haemost 2003; 1: 1138–1139.

    Article  CAS  Google Scholar 

  48. ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207–1212.

    Article  CAS  Google Scholar 

  49. Pihusch R, Salat C, Schimdt E, Gohring P, Pihusch M, Hiller E et al. Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation 2002; 74: 1303–1309.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servizio di Immunoematologia e Trasfusione – Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy

    M Franchini

  2. Dipartimento di Medicina Clinica e Sperimentale, Sezione di Ematologia, Università di Verona, Verona, Italy

    D Veneri

  3. Dipartimento di Scienze Biomediche e Morfologiche, Istituto di Chimica e Microscopia Clinica, Università di Verona, Verona, Italy

    G Lippi

Authors
  1. M Franchini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Veneri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Lippi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Franchini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Franchini, M., Veneri, D. & Lippi, G. The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. Bone Marrow Transplant 39, 729–735 (2007). https://doi.org/10.1038/sj.bmt.1705670

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705670

Keywords

This article is cited by

Search

Advanced search

Quick links